Is bromantane better than phenylpiracetam?

On this data, yes, and not narrowly. Bromantane scores 7.1 against 5.5 and wins every shared use case that is not a floor tie: energy 6.2 to 5.3, cognition 5.8 to 5.2, stress 6.0 to 1.5, mood 5.5 to 1.5, sleep 4.0 to 1.5. Phenylpiracetam's only real edge is that a single dose reaches full effect in about two hours.

Why does phenylpiracetam stop working after a few days?

Tolerance, and it is the defining property of the compound rather than a sourcing problem. Its durability subscore is 2.2 out of 5.0 and its own report names tolerance as a main reason the score stays at 5.5. Raising the dose makes the side-effect profile worse without restoring the effect. Cycling off is the only workaround.

How long does bromantane take to work?

First noticeable effect at about two hours, full effect at about two weeks, on a four-week assessment window. That slow build is the mechanism working as intended: it demethylates the tyrosine hydroxylase promoter to raise dopamine synthesis capacity rather than forcing release. Judging it on day one against a phenylpiracetam dose measures the wrong thing.

Can I take bromantane and phenylpiracetam together?

Do not. Both raise dopaminergic tone, both carry an MAOI exclusion, and both list uncontrolled hypertension as a contraindication. Stacking them multiplies the cardiovascular and sleep cost with no mechanism story behind it. If you are moving between them, stop one before starting the other.

Are either of them safe to take every day?

Neither has human safety data past 28 days, so the honest answer is that nobody knows. Bromantane is dosed pulsed for that reason and its effect persists between doses, and Iezhitsa 2000 ran two months in rats with recovery and no tolerance. Phenylpiracetam cannot be taken daily for a different reason: it stops working.

Can I compete in a tested sport on either one?

No. Bromantane has been on WADA's S6.A stimulant list every year since 1997, and Burnat 1997 documents the Atlanta 1996 doping cases that put it there. Phenylpiracetam is listed as a banned stimulant on the current WADA list. In-competition tested sport is a contraindication on both source reports.

How much do they cost?

Bromantane runs about $12 to $30 a month on a pulsed 30 mg protocol, from bulk powder at $40 to $100 per gram. Phenylpiracetam runs about $21 to $42 a month at 100 to 200 mg daily. Both are September 2026 estimates. Neither includes the per-lot third-party certificate of analysis, which is the real added cost on a gray-market compound.

Who should not take bromantane?

Anyone pregnant or lactating, under 18, on an MAOI, competing in a tested sport, with bipolar I disorder or with uncontrolled hypertension. Add anyone unwilling to buy a lot-matched HPLC certificate: Vanhee 2025 found bromantane in illicit samples with one unit underdosed at 33.2 mg, which is what an unverified powder looks like in practice.

Head-to-Head Comparison

Bromantane vs Phenylpiracetam: Which Is Better for Energy?

Should I take bromantane or phenylpiracetam?

Reviewed 09/08/2026

Bromantane, for anything you plan to repeat. It scores 7.1 against phenylpiracetam's 5.5 and wins every shared use case that is not a floor tie: energy 6.2 to 5.3, stress 6.0 to 1.5, mood 5.5 to 1.5. The gap is tolerance. Bromantane builds over two weeks and holds. Phenylpiracetam peaks in an hour and fades within days, which is why it stays a one-session tool.

Bromantane 7.1, phenylpiracetam 5.5, and phenylpiracetam does not win a single shared use case. It ties at the floor on body composition, longevity and TBI, and loses the rest.
Durability decides it: 3.9 against 2.2. Bromantane's effect builds over two weeks. Phenylpiracetam's tolerates quickly, which its own report names as the reason the score stays low.
Their evidence bases are not comparable. Bromantane has a 728-patient Russian trial (Voznesenskaia 2010) and a placebo-controlled RCT (Neznamov 2009). Phenylpiracetam has one class review (Malykh 2010) covering racetams generally.
Bromantane is not a classical stimulant. It demethylates the tyrosine hydroxylase promoter to raise dopamine synthesis, which is why it works upward over weeks instead of borrowing from tomorrow.
Phenylpiracetam's one real advantage is speed of a single dose: full effect in about two hours against bromantane's two weeks. That makes it an occasional tool, not a protocol.
Cost is close. Bromantane runs $12 to $30 a month on a pulsed 30 mg protocol, phenylpiracetam $21 to $42 daily. Both are estimates and both need a third-party certificate of analysis.
Both are WADA-prohibited stimulants and both move through gray-market channels. Vanhee 2025 found bromantane in illicit samples, one underdosed at 33.2 mg per unit.

At a Glance

Option B

Phenylpiracetam (Phenotropil)

5.5 / 10 🤷 Neutral

Upside

Efficacy 3.5
Breadth 3.0
Evidence 3.0
Speed 4.0
Durability 2.2
Bioindividuality 2.8

Downside

Safety Risk 2.3
Side Effects 2.6
Cost 2.5
Effort 1.6
Opportunity Cost 2.2
Dependency 3.0
Reversibility 1.8

Best at:

Energy 5.3
Cognition Focus 5.2
Reaction Time 5.0
Cold Heat Tolerance 5.0

Phenylated racetam with stimulant character. BioHarmony 5.5, neutral.

Read full BioHarmony report →

Head-to-Head Verdict

Use Case	Winner	Rationale
Energy	Bromantane (Ladasten)	Bromantane 6.2 against phenylpiracetam's 5.3, and the mechanism explains why the gap widens with repetition. Bromantane is an actoprotector: Morozov and Kleimenova 1998 measured physical work capacity in rodents at 1.3 to 1.6 times phenamine, and Oliynyk 2012 reviews the class across heat and fatigue. Phenylpiracetam delivers a sharper first dose and less of the fourth.
Cognition Focus	Bromantane (Ladasten)	Bromantane 5.8 against 5.2, the narrowest gap on the page and the one where evidence quality does the deciding. Voznesenskaia 2010 gave 728 outpatients 50 to 100 mg/day for 28 days with a 76.0% CGI-S responder rate. Phenylpiracetam's entire clinical anchor is Malykh 2010, a systematic review of the piracetam class rather than a phenylpiracetam trial.
Stress Resilience	Bromantane (Ladasten)	Bromantane 6.0 against phenylpiracetam's 1.5, and this is the row that separates an actoprotector from a stimulant. Neznamov 2008 stratified responders by baseline EEG alpha and found a dual profile: psychostimulant in some patients, anxiolytic in others. Phenylpiracetam has no anxiolytic arm at all and its report lists anxiety disorders as a contraindication.
Anxiety	Bromantane (Ladasten)	Bromantane 5.7 against 1.5. Bromantane modulates GABA-A alongside its dopaminergic action, and the Russian trials treated asthenic and neurasthenic patients where anxiety is part of the presentation. Phenylpiracetam pushes dopaminergic tone with no counterweight, which is why anxiety disorders and stimulant sensitivity are both on its exclusion list.
Mood	Bromantane (Ladasten)	Bromantane 5.5 against 1.5. Tallerova 2011 found a depression-like syndrome model in mice where bromantane was more potent than imipramine on TNF-alpha and IL-6, and depression scores 3.5 on its own report against phenylpiracetam's 1.5. Animal data on an inflammatory endpoint, not a human antidepressant claim, but phenylpiracetam has nothing here.
Sleep Quality	Bromantane (Ladasten)	Bromantane 4.0 against phenylpiracetam's 1.5, which is a win by not causing harm. Phenylpiracetam's own contraindication list names insomnia and any need to dose late in the day. Bromantane's Russian pharmacovigilance reported a 3% adverse event rate and 0.8% discontinuation across 728 patients, and Neznamov 2009 found no withdrawal syndrome after a one-week washout.
Flow State	Bromantane (Ladasten)	Bromantane 4.2 against 1.5. The relevant difference is that bromantane raises dopamine synthesis capacity rather than forcing release, so the subjective quality is described as clean rather than driven. Mikhaylova 2007 showed D1 and D5 dependent transformation of hippocampal long-term potentiation in rats, which is the closest mechanistic support either side has for this row.
Neuroplasticity	Bromantane (Ladasten)	Bromantane 4.5 against 1.5. Salimgareeva 2012 documented BDNF and NGF mRNA upregulation with pERK1/2 rising 70% at half an hour, and Mikhaylova 2007 showed the hippocampal LTP effect. That is a genuine mechanistic case in animals. Phenylpiracetam's cholinergic receptor density changes are described in its report without a plasticity endpoint attached.
Endurance Cardio	Bromantane (Ladasten)	Bromantane 3.5 against 1.5. This is the original military use case: actoprotectors were developed for work capacity under heat, hypoxia and fatigue, and Burnat 1997 documents how the West first met bromantane through Atlanta 1996 doping cases rather than through therapeutics. Neither compound is usable by a tested athlete, so treat this as history.
Body Composition	Tie	Both 1.5, an exact floor tie. Neither compound has a body-composition mechanism or claim. Phenylpiracetam's appetite suppression comes with its stimulant character and is not a fat-loss route either report supports. This row exists to close off a use people try anyway.
Longevity	Tie	Both 1.5. Neither has longitudinal human data. The closest thing on either side is Iezhitsa 2000, a two-month bromantane course in rats showing recovery within two months and no tolerance, which the bromantane report uses to stand in for the missing human safety data past 28 days. That is a safety proxy, not a longevity finding.
TBI	Tie	Both 1.5, and both scores mean absence rather than a measured null. No human trial on either compound has enrolled a head-injury population. If you are here for post-concussion recovery, both source reports point elsewhere.

Cost Comparison

Intervention	Monthly Cost	Notes
Bromantane	$12 to $30	ESTIMATE, priced 2026-09-07, research-chemical channel. Bulk powder runs $40 to $100 per gram, and a 30 mg pulsed dose taken about ten mornings a month consumes 0.3 g. The pulsing is what makes it cheap: it is dosed intermittently by design because the effect builds and persists, not because you are rationing it. Add a third-party HPLC assay per lot.
Phenylpiracetam	$21 to $42	ESTIMATE, priced 2026-09-08, nootropic vendor retail. Sixty 100 mg capsules list around $42, so 100 mg/day is about $21 a month and 200 mg/day about $42. Cycled use costs less, and cycling is mandatory rather than optional here given how quickly it tolerates. A third-party certificate of analysis is the real added expense on either compound.
The difference	Bromantane is cheaper per month and far cheaper per useful day	On paper bromantane runs about $9 to $12 a month less. The real gap is wider than that, because the two products deliver different numbers of useful days for the money.Bromantane's durability score is 3.9 out of 5.0 and its effect builds over two weeks, so a pulsed month of ten doses covers the month. Phenylpiracetam scores 2.2 and tolerates within days, so the same spend buys a handful of good sessions and then diminishing ones. Neither figure includes the per-lot certificate of analysis.

When to Switch

These two need completely different evaluation schedules and getting that wrong is the most common mistake with the pair. Phenylpiracetam reaches first noticeable effect in about an hour and full effect in about two, with a two-week assessment window that is really about whether tolerance has already eaten it.

Bromantane starts in about two hours but does not reach full effect for two weeks, on a four-week window. Judging bromantane on day one against a phenylpiracetam dose is judging the wrong thing.

Switch from phenylpiracetam to bromantane when the pattern is that it worked brilliantly for three days and then stopped. That is the expected course rather than a sourcing problem: durability 2.2 against 3.9, and phenylpiracetam's own report names tolerance as a primary reason its score stays at 5.5.

Also switch if you are dosing later in the day to chase the fade, because insomnia is on its contraindication list and sleep quality runs 1.5 against bromantane's 4.0.

There is one honest reason to go the other way, and it is narrow. Phenylpiracetam is the only one of the two that delivers a full effect inside a single morning. If what you need is one hard cognitive session this week and you will not repeat it, that acute profile is a real advantage, provided you are not a tested athlete, not anxiety-prone and not stimulant-sensitive.

Do not run them together. Both raise dopaminergic tone, both carry an MAOI exclusion, and stacking them multiplies the cardiovascular and sleep cost with no mechanism story behind it.

Who Should Pick What?

Someone who wants a daily cognitive baseline they can sustain

Bromantane (Ladasten)

Durability 3.9 against 2.2, and Iezhitsa 2000 ran a two-month rat course showing recovery within two months and no tolerance. Voznesenskaia 2010 dosed 728 outpatients for 28 days with a 3% adverse event rate. Even so, run it pulsed rather than truly daily, because human safety data past 28 days does not exist.

Anyone whose fatigue comes packaged with anxiety or low mood

Bromantane (Ladasten)

Anxiety 5.7 against 1.5, stress resilience 6.0 against 1.5, mood 5.5 against 1.5. Neznamov 2008 found bromantane behaves as a psychostimulant or an anxiolytic depending on baseline EEG alpha, which is exactly the profile this person needs. Phenylpiracetam lists anxiety disorders as a contraindication, so it is the wrong direction entirely.

Person who needs one hard session this week and will not repeat it

Phenylpiracetam (Phenotropil)

This is the only place it wins, and it wins on kinetics rather than on any subrating. Full effect in about two hours against bromantane's two weeks. Take 100 mg in the morning, do the work, do not take it again for a while. Not for anyone stimulant-sensitive, anxiety-prone, hypertensive or on an MAOI.

Someone who has been taking phenylpiracetam daily for a month

Bromantane (Ladasten)

Tolerance is why it stopped working, and taking more will not fix it. Its durability score is 2.2 and its own report names tolerance as the reason the overall score sits at 5.5. Stop, sleep properly for a week, then consider a pulsed 30 mg bromantane protocol on a four-week window rather than escalating the dose you are on.

Competing athlete in a tested sport

Tie

Neither, without ambiguity. Bromantane has been on WADA's S6.A stimulant list every year since 1997 and the West first encountered it through Atlanta 1996 doping cases (Burnat 1997). Phenylpiracetam is likewise listed. Both source reports name in-competition tested sport as a contraindication.

Anyone with bipolar I disorder, uncontrolled hypertension, or on an MAOI

Tie

Neither. MAOI co-administration and uncontrolled hypertension are on both contraindication lists, and bromantane adds bipolar I explicitly. Both act on dopaminergic transmission, so the interaction concern is the same compound class problem rather than a quirk of one product.

Someone unwilling to pay for a per-lot certificate of analysis

Tie

Neither. Both are gray market with purity verification required, and both reports treat an unverified product as a contraindication in its own right. Vanhee 2025 found bromantane in illicit samples with one unit underdosed at 33.2 mg. Without an HPLC result you are guessing at both identity and dose.

Anyone hoping either one helps with recovery from a head injury

Tie

Neither. Both score 1.5 on TBI and that number reflects an absence of studies rather than a measured null. No human trial on either compound has enrolled a head-injury population. Bromantane's neurotrophic data (Salimgareeva 2012) is rodent mRNA work, which is a hypothesis, not a treatment.

Research Highlights

Mechanism Difference
Bromantane is not a stimulant in the way phenylpiracetam is, and that is the whole comparison. Bromantane induces tyrosine hydroxylase gene expression by demethylating the TH promoter, documented by Vakhitova 2006, and adds weak dopamine reuptake inhibition plus BDNF and NGF upregulation. It raises the capacity to make dopamine rather than forcing release of what is there.Phenylpiracetam is piracetam with a phenyl group attached, which gives it stimulant character: raised dopaminergic tone plus NMDA, AMPA and nicotinic receptor modulation for a fast focus effect. Building synthesis capacity takes two weeks and holds. Pushing transmission takes an hour and fades, which is why durability runs 3.9 against 2.2.
Safety Comparison
Both are prohibited stimulants sold through gray-market channels, and both require a third-party certificate of analysis before use. Shared exclusions are pregnancy, breastfeeding, MAOI co-administration, uncontrolled hypertension and tested sport. Bromantane adds bipolar I disorder and being under 18.Phenylpiracetam adds the ones that follow from stimulant character: stimulant sensitivity, anxiety disorders, insomnia or any need to dose late, cardiovascular disease, concurrent stimulant medication, and a history of stimulant misuse. Its downside total is 1.747 against bromantane's 0.892, and side effects score 2.6 against 1.7.
Cost Comparison
Bromantane runs about $12 to $30 a month on a pulsed 30 mg protocol taken roughly ten mornings, from bulk powder at $40 to $100 per gram. Phenylpiracetam runs about $21 to $42 a month at 100 to 200 mg daily. Both are estimates priced September 2026 and neither includes the per-lot certificate of analysis.The monthly gap understates the difference. Bromantane's effect builds and persists, so ten doses cover a month. Phenylpiracetam tolerates within days, so the same money buys a few strong sessions followed by weaker ones, and the standard workaround is cycling off rather than taking more.
Editorial Verdict
Bromantane scores 7.1 and phenylpiracetam 5.5, and phenylpiracetam does not win a single shared use case. It ties at the floor on body composition, longevity and TBI, and loses energy 5.3 to 6.2, cognition 5.2 to 5.8, stress 1.5 to 6.0, mood 1.5 to 5.5 and sleep 1.5 to 4.0.The evidence bases are not comparable either. Bromantane holds a 728-patient Russian trial with a 76.0% responder rate and the only published placebo-controlled RCT in the pair. Phenylpiracetam's clinical anchor is a systematic review of the piracetam class generally. Take phenylpiracetam only for a single session you will not repeat.
Durability
Durability is the deciding dimension: 3.9 for bromantane against 2.2 for phenylpiracetam. Bromantane's effect accrues over about two weeks on a four-week assessment window, and Neznamov 2009, the only published placebo-controlled trial, found no withdrawal syndrome after a one-week washout. Iezhitsa 2000 ran two months in rats with recovery and no tolerance.Phenylpiracetam reaches full effect in about two hours and tolerates quickly, which its own report names as the main reason the score stays at 5.5. Neither has human safety data past 28 days, so pulse bromantane rather than taking it continuously and cycle phenylpiracetam because you have no choice.

Frequently Asked Questions

Is bromantane better than phenylpiracetam?: On this data, yes, and not narrowly. Bromantane scores 7.1 against 5.5 and wins every shared use case that is not a floor tie: energy 6.2 to 5.3, cognition 5.8 to 5.2, stress 6.0 to 1.5, mood 5.5 to 1.5, sleep 4.0 to 1.5. Phenylpiracetam's only real edge is that a single dose reaches full effect in about two hours.
Why does phenylpiracetam stop working after a few days?: Tolerance, and it is the defining property of the compound rather than a sourcing problem. Its durability subscore is 2.2 out of 5.0 and its own report names tolerance as a main reason the score stays at 5.5. Raising the dose makes the side-effect profile worse without restoring the effect. Cycling off is the only workaround.
How long does bromantane take to work?: First noticeable effect at about two hours, full effect at about two weeks, on a four-week assessment window. That slow build is the mechanism working as intended: it demethylates the tyrosine hydroxylase promoter to raise dopamine synthesis capacity rather than forcing release. Judging it on day one against a phenylpiracetam dose measures the wrong thing.
Can I take bromantane and phenylpiracetam together?: Do not. Both raise dopaminergic tone, both carry an MAOI exclusion, and both list uncontrolled hypertension as a contraindication. Stacking them multiplies the cardiovascular and sleep cost with no mechanism story behind it. If you are moving between them, stop one before starting the other.
Are either of them safe to take every day?: Neither has human safety data past 28 days, so the honest answer is that nobody knows. Bromantane is dosed pulsed for that reason and its effect persists between doses, and Iezhitsa 2000 ran two months in rats with recovery and no tolerance. Phenylpiracetam cannot be taken daily for a different reason: it stops working.
Can I compete in a tested sport on either one?: No. Bromantane has been on WADA's S6.A stimulant list every year since 1997, and Burnat 1997 documents the Atlanta 1996 doping cases that put it there. Phenylpiracetam is listed as a banned stimulant on the current WADA list. In-competition tested sport is a contraindication on both source reports.
How much do they cost?: Bromantane runs about $12 to $30 a month on a pulsed 30 mg protocol, from bulk powder at $40 to $100 per gram. Phenylpiracetam runs about $21 to $42 a month at 100 to 200 mg daily. Both are September 2026 estimates. Neither includes the per-lot third-party certificate of analysis, which is the real added cost on a gray-market compound.
Who should not take bromantane?: Anyone pregnant or lactating, under 18, on an MAOI, competing in a tested sport, with bipolar I disorder or with uncontrolled hypertension. Add anyone unwilling to buy a lot-matched HPLC certificate: Vanhee 2025 found bromantane in illicit samples with one unit underdosed at 33.2 mg, which is what an unverified powder looks like in practice.

Evidence Sources

RCT Voznesenskaia 2010, Treatment of asthenic disorders in patients with psychoautonomic syndrome (2010) n=728 outpatients, 50 to 100 mg/day for 28 days. CGI-S responder 76.0%, CGI-I responder 90.8%, adverse events 3%, discontinuation 0.8%. Open-label.
RCT Neznamov 2009, Ladasten in the treatment of neurasthenia, placebo-controlled comparative study (2009) The only published placebo-controlled bromantane RCT. 28 days plus a one-week washout, with no withdrawal syndrome.
Preclinical Mikhaylova 2007, Effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats (2007) D1 and D5 dependent transformation of hippocampal long-term potentiation. The most rigorous mechanistic paper and the only Western-journal placement.
Preclinical Vakhitova 2006, Cytosine demethylation in the TH gene promoter under the action of ladasten (2006) Epigenetic activation of tyrosine hydroxylase transcription. The strongest mechanistic finding behind the build-then-hold profile.
Preclinical Salimgareeva 2012, Activation of gene expression for neurotrophins and MAP kinases (2012) BDNF and NGF mRNA upregulation with pERK1/2 rising about 70% at 30 minutes.
RCT Neznamov 2008, Ladasten effect in neurasthenia patients with various EEG parameters (2008) EEG-stratified responder analysis showing a dual mechanism: psychostimulant or anxiolytic depending on baseline alpha.
Review Oliynyk and Oh 2012, The pharmacology of actoprotectors (2012) Narrative review of the actoprotector class covering heat, hypoxia, carbon monoxide and fatigue protection. The closest Western touchpoint.
Review Morozov 1999, The mechanisms of the neurotropic action of bromantan (1999) Landmark mechanism review for the compound.
Preclinical Tallerova 2011, Effect of ladasten on cytokine markers in mice with depression-like syndrome (2011) More potent than imipramine on TNF-alpha and IL-6 in an animal depression model.
Preclinical Iezhitsa 2000, Two-month bromantane course in rats (2000) Recovery within two months and no tolerance. The closest analog to the missing human safety data beyond 28 days.
Preclinical Morozov and Kleimenova 1998, Bromantane increases physical work capacity in mice and rats (1998) Effect 1.3 to 1.6 times phenamine with duration over 24 hours.
Case report Burnat 1997, Bromontan, a new doping agent (1997) Western recognition of bromantane arrived through the Atlanta 1996 doping cases rather than through therapeutic use.
Review Docherty 2008, Pharmacology of stimulants prohibited by WADA (2008) Classifies bromantane as serotonergic and dopaminergic, with Atlanta and Sydney positives on record.
Forensic Vanhee 2025, Multi-laboratory European and Australian surveillance of illicit nootropics (2025) Bromantane detected in two illicit samples, one underdosed at 33.2 mg per unit. Direct evidence for the certificate-of-analysis requirement.
Regulatory WADA 2025 Prohibited List (2025) Bromantane has appeared on S6.A stimulants on every annual list since 1997.
Systematic review Malykh 2010, Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders (2010) Systematic review of the piracetam class across cognition, stroke, epilepsy and stress. Phenylpiracetam's only clinical anchor, and it is class-level rather than compound-specific.
Regulatory WADA 2026 Prohibited List (2026) Phenylpiracetam is listed as a banned stimulant, so any drug-tested athlete risks a failed test.
Authority gap ClinicalTrials.gov registry check for phenylpiracetam (2026) Checked for registered phenylpiracetam studies. The result underscores how little modern Western clinical work exists.

Glossary

Quick reference for the medical and technical terms used in this comparison.

Actoprotector Actoprotector: A Soviet-era drug class defined by raising work capacity under stress such as heat, hypoxia and fatigue without classical stimulant properties. Bromantane is the best-known member.
TH Tyrosine Hydroxylase: The rate-limiting enzyme in dopamine synthesis. Bromantane demethylates its gene promoter to raise expression, which is why its effect builds over two weeks instead of arriving in an hour.
BDNF Brain-Derived Neurotrophic Factor: A growth factor involved in synaptic plasticity. Salimgareeva 2012 documented bromantane raising its mRNA alongside NGF in rodents.
CGI-S Clinical Global Impression, Severity: A clinician-rated severity scale. Voznesenskaia 2010 reported a 76.0% responder rate on it across 728 outpatients, the largest single dataset in this comparison.
LTP Long-Term Potentiation: The strengthening of synapses that underlies learning. Mikhaylova 2007 showed bromantane transforms hippocampal LTP through D1 and D5 receptors in rats.
Racetam Racetam: The nootropic class built on the 2-pyrrolidone core, starting with piracetam. Adding a phenyl group produces phenylpiracetam and with it the stimulant character and the tolerance.
COA Certificate of Analysis: A lot-matched third-party HPLC result confirming identity and dose. Required for both compounds, and neither price estimate includes it.
WADA S6.A WADA Prohibited List Section S6.A: The non-specified stimulants category, prohibited in competition. Bromantane has appeared there on every annual list since 1997, and phenylpiracetam is likewise banned.

Nick Urban Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

Our bromantane report records it as actively using at 7.5, on a 30 mg pulsed morning protocol

Reviewed Sep 8, 2026 · next review Dec 7, 2026

Find which one fits your biology

Take the BioHarmony Quiz